The  ||| S:0 E:4 ||| DT
role  ||| S:4 E:9 ||| NN
of  ||| S:9 E:12 ||| IN
hormonal  ||| S:12 E:21 ||| JJ
therapy  ||| S:21 E:29 ||| NN
in  ||| S:29 E:32 ||| IN
osteoporosis  ||| S:32 E:45 ||| NN
In  ||| S:45 E:48 ||| IN
developed  ||| S:48 E:58 ||| JJ
societies ||| S:58 E:67 ||| NNS
,  ||| S:67 E:69 ||| ,
the  ||| S:69 E:73 ||| DT
post-menopausal  ||| S:73 E:89 ||| JJ
period  ||| S:89 E:96 ||| NN
covers  ||| S:96 E:103 ||| VBZ
approximately  ||| S:103 E:117 ||| RB
one  ||| S:117 E:121 ||| CD
third  ||| S:121 E:127 ||| JJ
of  ||| S:127 E:130 ||| IN
a  ||| S:130 E:132 ||| DT
woman ||| S:132 E:137 ||| NN
's  ||| S:137 E:140 ||| POS
life ||| S:140 E:144 ||| NN
.  ||| S:144 E:146 ||| .
The  ||| S:146 E:150 ||| DT
deficit  ||| S:150 E:158 ||| NN
of  ||| S:158 E:161 ||| IN
oestrogens  ||| S:161 E:172 ||| NN
observed  ||| S:172 E:181 ||| VBD
during  ||| S:181 E:188 ||| IN
the  ||| S:188 E:192 ||| DT
post-menopausal  ||| S:192 E:208 ||| JJ
period  ||| S:208 E:215 ||| NN
significantly  ||| S:215 E:229 ||| RB
affects  ||| S:229 E:237 ||| VBZ
the  ||| S:237 E:241 ||| DT
course  ||| S:241 E:248 ||| NN
of  ||| S:248 E:251 ||| IN
many  ||| S:251 E:256 ||| JJ
metabolic  ||| S:256 E:266 ||| JJ
processes ||| S:266 E:275 ||| NNS
,  ||| S:275 E:277 ||| ,
causing  ||| S:277 E:285 ||| VBG
a  ||| S:285 E:287 ||| DT
number  ||| S:287 E:294 ||| NN
of  ||| S:294 E:297 ||| IN
diseases  ||| S:297 E:306 ||| NNS
and  ||| S:306 E:310 ||| CC
in  ||| S:310 E:313 ||| IN
consequence  ||| S:313 E:325 ||| NN
diminishing  ||| S:325 E:337 ||| VBG
quality  ||| S:337 E:345 ||| NN
of  ||| S:345 E:348 ||| IN
life ||| S:348 E:352 ||| NN
.  ||| S:352 E:354 ||| .
Among  ||| S:354 E:360 ||| IN
others ||| S:360 E:366 ||| NNS
,  ||| S:366 E:368 ||| ,
bones  ||| S:368 E:374 ||| NNS
belong  ||| S:374 E:381 ||| VBP
to  ||| S:381 E:384 ||| TO
oestrogen-dependent  ||| S:384 E:404 ||| JJ
tissues ||| S:404 E:411 ||| NNS
.  ||| S:411 E:413 ||| .
The  ||| S:413 E:417 ||| DT
deficit  ||| S:417 E:425 ||| NN
of  ||| S:425 E:428 ||| IN
the  ||| S:428 E:432 ||| DT
protective  ||| S:432 E:443 ||| JJ
influence  ||| S:443 E:453 ||| NN
of  ||| S:453 E:456 ||| IN
oestrogens  ||| S:456 E:467 ||| JJ
compromises  ||| S:467 E:479 ||| NNS
the  ||| S:479 E:483 ||| DT
dynamic  ||| S:483 E:491 ||| JJ
balance  ||| S:491 E:499 ||| NN
of  ||| S:499 E:502 ||| IN
the  ||| S:502 E:506 ||| DT
bone  ||| S:506 E:511 ||| NN
transformation  ||| S:511 E:526 ||| NN
process  ||| S:526 E:534 ||| NN
towards  ||| S:534 E:542 ||| IN
resorption ||| S:542 E:552 ||| NN
,  ||| S:552 E:554 ||| ,
thus  ||| S:554 E:559 ||| RB
reducing  ||| S:559 E:568 ||| VBG
bone  ||| S:568 E:573 ||| NN
mass  ||| S:573 E:578 ||| NN
and  ||| S:578 E:582 ||| CC
quality ||| S:582 E:589 ||| NN
,  ||| S:589 E:591 ||| ,
while  ||| S:591 E:597 ||| IN
increasing  ||| S:597 E:608 ||| VBG
the  ||| S:608 E:612 ||| DT
risk  ||| S:612 E:617 ||| NN
of  ||| S:617 E:620 ||| IN
low-energy  ||| S:620 E:631 ||| JJ
fractures ||| S:631 E:640 ||| NN
.  ||| S:640 E:642 ||| .
In  ||| S:642 E:645 ||| IN
recent  ||| S:645 E:652 ||| JJ
years ||| S:652 E:657 ||| NNS
,  ||| S:657 E:659 ||| ,
differing  ||| S:659 E:669 ||| VBG
views  ||| S:669 E:675 ||| NNS
on  ||| S:675 E:678 ||| IN
the  ||| S:678 E:682 ||| DT
application  ||| S:682 E:694 ||| NN
of  ||| S:694 E:697 ||| IN
oestrogen ||| S:697 E:706 ||| CD
/ ||| S:706 E:707 ||| CD
gestagen  ||| S:707 E:716 ||| CD
therapy  ||| S:716 E:724 ||| NNS
have  ||| S:724 E:729 ||| VBP
reached  ||| S:729 E:737 ||| VBN
the  ||| S:737 E:741 ||| DT
level  ||| S:741 E:747 ||| NN
of  ||| S:747 E:750 ||| IN
controversy ||| S:750 E:761 ||| NN
.  ||| S:761 E:763 ||| .
The  ||| S:763 E:767 ||| DT
results  ||| S:767 E:775 ||| NNS
of  ||| S:775 E:778 ||| IN
numerous  ||| S:778 E:787 ||| JJ
clinical  ||| S:787 E:796 ||| JJ
studies  ||| S:796 E:804 ||| NNS
are  ||| S:804 E:808 ||| VBP
far  ||| S:808 E:812 ||| RB
from  ||| S:812 E:817 ||| IN
unequivocal ||| S:817 E:828 ||| NN
,  ||| S:828 E:830 ||| ,
with  ||| S:830 E:835 ||| IN
the  ||| S:835 E:839 ||| DT
whole  ||| S:839 E:845 ||| JJ
subject  ||| S:845 E:853 ||| JJ
one  ||| S:853 E:857 ||| NN
of  ||| S:857 E:860 ||| IN
heated  ||| S:860 E:867 ||| JJ
debate ||| S:867 E:873 ||| NN
.  ||| S:873 E:875 ||| .
It  ||| S:875 E:878 ||| PRP
has  ||| S:878 E:882 ||| VBZ
been  ||| S:882 E:887 ||| VBN
confirmed  ||| S:887 E:897 ||| VBN
that  ||| S:897 E:902 ||| IN
hormonal  ||| S:902 E:911 ||| JJ
therapy  ||| S:911 E:919 ||| NN
prevents  ||| S:919 E:928 ||| VBZ
bone  ||| S:928 E:933 ||| JJ
quality  ||| S:933 E:941 ||| NN
deterioration ||| S:941 E:954 ||| NN
,  ||| S:954 E:956 ||| ,
while  ||| S:956 E:962 ||| IN
opening  ||| S:962 E:970 ||| VBG
a  ||| S:970 E:972 ||| DT
protective  ||| S:972 E:983 ||| JJ
umbrella  ||| S:983 E:992 ||| NN
around  ||| S:992 E:999 ||| IN
the  ||| S:999 E:1003 ||| DT
bone ||| S:1003 E:1007 ||| NN
,  ||| S:1007 E:1009 ||| ,
reducing  ||| S:1009 E:1018 ||| VBG
the  ||| S:1018 E:1022 ||| DT
risk  ||| S:1022 E:1027 ||| NN
of  ||| S:1027 E:1030 ||| IN
osteoporotic  ||| S:1030 E:1043 ||| JJ
fractures ||| S:1043 E:1052 ||| NN
.  ||| S:1052 E:1054 ||| .
A  ||| S:1054 E:1056 ||| DT
rational  ||| S:1056 E:1065 ||| JJ
approach  ||| S:1065 E:1074 ||| NN
to  ||| S:1074 E:1077 ||| TO
weighing  ||| S:1077 E:1086 ||| VB
possible  ||| S:1086 E:1095 ||| JJ
advantages  ||| S:1095 E:1106 ||| NNS
against  ||| S:1106 E:1114 ||| IN
possible  ||| S:1114 E:1123 ||| JJ
risks  ||| S:1123 E:1129 ||| NNS
and  ||| S:1129 E:1133 ||| CC
a  ||| S:1133 E:1135 ||| DT
thorough  ||| S:1135 E:1144 ||| JJ
evaluation  ||| S:1144 E:1155 ||| NN
of  ||| S:1155 E:1158 ||| IN
a  ||| S:1158 E:1160 ||| DT
patient ||| S:1160 E:1167 ||| NN
's  ||| S:1167 E:1170 ||| POS
health  ||| S:1170 E:1177 ||| NN
condition  ||| S:1177 E:1187 ||| NN
allows  ||| S:1187 E:1194 ||| VBZ
for  ||| S:1194 E:1198 ||| IN
optimal  ||| S:1198 E:1206 ||| JJ
therapy  ||| S:1206 E:1214 ||| NN
selection ||| S:1214 E:1223 ||| NN
.  ||| S:1223 E:1225 ||| .
